Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema

Ophthalmology

Volumn 110, Issue 9, 2003, Pages 1690-1696

  Funatsu, Hideharu ^a   Yamashita, Hidetoshi ^b   Ikeda, Tomohiro ^a,c   Mimura, Tatsuya ^d   Eguchi, Shuichiro ^e   Hori, Sadao ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e Eguchi Eye Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL PERMEABILITY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIABETIC MACULAR EDEMA; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETINA MACULA EDEMA; RETINA SURGERY; RETROSPECTIVE STUDY; VITREOUS BODY; VITREOUS BODY DETACHMENT;

EID: 0042932650     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00568-2     Document Type: Article

References (27)

1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003.
2. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-32.
3. Lewis H. The role of vitrectomy in the treatment of diabetic macular edema. Am J Ophthalmol 2001;131:123-5.
4. Penn State Retina Research Group, Antonetti DA, Barber AJ, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998;47:1953-9.
5. Cohen T, Nahari D, Cerem LW, et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-41.
6. Maruo N, Morita I, Shirao M, Murota S. IL-6 increases endothelial permeability in vitro. Endocrinology 1992;131: 710-4.
7. Funatsu H, Yamashita H, Shimizu E, et al. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 2001;21:469-77.
8. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-7.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-7.
10. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS Report Number 10. Ophthalmology 1991; 98(5 suppl):786-806.
11. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report Number 12. Ophthalmology 1991;98(5 Suppl):823-33.
12. Funatsu H, Yamashita H, Ikeda T, et al. Relationship of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol 2003;135:321-7.
13. Hyodo I, Doi T, Endo H, et al. Clinical significance plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998;34:2041-5.
14. Grey A, Mitnick MA, Shapses S, et al. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperperparathyroidism and correlate with markers of bone resorption-a clinical research center study. J Clin Endocrinol Metab 1996;81:3450-4.
15. Hernandez C, Burgos R, Canton A, et al. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case control study. Diabetes Care 2001;24:516-21.
16. SAS/STAT Software: changes and enhancements through release 6.12. Cary, NC: SAS Publishing; 1997.
17. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992;99: 753-9.
18. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 2001; 132:369-77.
19. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 1996;122: 258-60.
20. Lutty GA, McLeod S, Merges C, et al. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996;114:971-7.
21. Burgos R, Simo R, Audi L, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 1997;40: 1107-9.
22. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
23. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
24. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform- selective inhibitor. Diabetes 1997;46:1473-80.
25. Punglia RS, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 1997;46:1619-26.
26. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 1996; 45:954-9.
27. Jumper MJ, Embabi SN, Toth CA, et al. Electron immunocytochemical analysis of posterior hyaloid associated with diabetic macular edema. Retina 2000;20:63-8.